25TH ANNUAL SCIENTIFIC ASSEMBLY
MARCH 9-13, 2019 • CAESARS PALACE • LAS VEGAS, NV
MARCH 9-13, 2019 • CAESARS PALACE • LAS VEGAS, NV
Jointly provided by the American Academy of Addiction Psychiatry, a DATA 2000 sponsoring organization and Providers Clinical Support System
Physicians are required to complete eight hours (and nurse practitioners and physician assistants are required to complete 24 hours) of medication assisted treatment (MAT) training to apply to the Drug Enforcement Agency for a waiver (“X-license”) to prescribe buprenorphine, one of three medications (buprenorphine, naltrexone and methadone) approved by the FDA for the treatment of opioid use disorder.
Emergency physicians have an opportunity to profoundly impact the deadly opioid epidemic by bridging patients to addiction treatment from the ED with buprenorphine. Along with the X-license, the information in the course will facilitate this life-saving, and potentially life-transforming, intervention.
← Back to all pre-conference courses
Register Today!
Add this course when you register for AAEM19.
The American Academy of Emergency Medicine designates this live activity for a maximum of 9 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of physician participation in the learning process: Credit will only be awarded for completing all of the training. To be awarded a maximum of 9 AMA PRA Category 1 Credits™ and a Buprenorphine Training Completion Certificate you must complete all 8 hours of the course. Those completing the course will be able to complete the waiver application online.
Funding for this initiative was made possible (in part) by grant nos. 5U79TI026556-02 and 3U79TI026556-02S1 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
1. Review addiction treatment in office-based practices
2. Discuss the pharmacological treatments of opioid use disorder
3. Determine what medical record documentation must be followed
4. Discuss the process of buprenorphine induction as well as stabilization and maintenance techniques
5. Describe how to take a patient history and evaluation
6. Review safety concerns and drug interactions
Please confirm your eligibility prior to registering: To apply for a waiver you must have a valid medical license and an active DEA number. Residents may take the course and apply for their waiver when they receive their DEA license. Medical students are also welcome to take the course.
Saturday, March 9, 2019
|
8:00am-8:30am |
Overview and Welcome |
|
8:30am-9:00am |
Neurobiology |
|
9:00am-10:00am |
Small Group/Case #1: Addicted School Teacher* |
|
10:45am-11:00am |
Break |
|
11:00am-11:45am |
Pharmacology |
|
11:45am-12:15pm |
Specialty Topics |
|
12:15pm-1:15pm |
Lunch (included with course fee) and Patient Panel |
|
1:15pm-2:00pm |
Medication Assisted Treatment (MAT) and Urine Drug Testing |
|
2:00pm-2:45pm |
Small Group/Case #2: Addiction and Depression* |
|
2:45pm-3:25pm |
Evidence-Based Counseling |
|
3:25pm-4:00pm |
Clinical Management |
|
4:00pm-4:45pm |
Small Group/Case #3: Setting Treatment Goals* |
|
4:45pm-5:15pm |
Completion of DEA Waiver; Questions and Answers; Evaluations |
|
5:15pm-5:30pm |
Sign-out |
*Please go to your assigned breakout section.
Eric Ketcham, MD MBA FAAEM FACEP FASAM FACHE
Department of Emergency Medicine & Department of Behavioral Health – Addiction Medicine Consult Service, Presbyterian Health System, Santa Fe & Espanola, NM; Medical Director, New Mexico Treatment Services (Opioid Addiction Treatment Program), Farmington & Santa Fe, NM; Co-Medical Director, multiple EMS & Fire Departments, NM & AZ
Andrew Herring, MD FAAEM FACEP
Highland Hospital Emergency Department, San Francisco, CA
